Nanostring Tech (NSTG) Tops Q2 EPS by 7c; Receives Approval in Australia for Prosigna Assay
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
NanoString Technologies Releases Financial Results for Second Quarter of 2014
August 5, 2014 4:01 PM EDT- Strong Q2 2014 Revenue Growth of 51% Year over Year - - Initiation of First Companion Diagnostic Collaboration with Celgene Corporation -
SEATTLE, Aug. 5, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the quarter ended June 30, 2014.
Financial Highlights:
Record total revenue of $10.9 million, 51% year-over-year growth Instrument revenue of $3.8 million, 49% year-over-year growth Cumulative installed base of approximately 220 nCounter® Analysis Systems and 500 publications Record... More